3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
40
HER2 Positive Metastatic Breast Cancer
4
Breast Diseases
4
Brain Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
HER2-positive Breast Cancer
2
Colorectal Neoplasms
2
Advanced Breast Cancer
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Salivary Gland Neoplasms
1
Pathologic Complete Response
1
Neoplasm Metastasis
1
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
1
HER2-positive Metastatic Breast Cancer
1
HER2+ Early or Locally Advanced Breast Cancer
1
HER2+ Breast Cancer
1
HER2 Positive Gastric Cancer
1
HER2 Positive Breast Cancer
1
HER-2 Positive Colorectal Cancer
1
Estrogen Receptor-positive Breast Cancer
1
Digestive System Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Fluorouracil
18
Oxaliplatin
17
Capecitabine
16
Leucovorin
13
Cisplatin
12
Gemcitabine
11
Drug Therapy
11
Irinotecan
10
Radiosurgery
9
Cetuximab
9
Bevacizumab
9
pembrolizumab
8
Docetaxel
8
Everolimus
7
spartalizumab
6
Sunitinib
6
Radiotherapy
6
Paclitaxel
6
Neoadjuvant Therapy
6
Cyclophosphamide
6
Trastuzumab
5
S 1 (combination)
5
Nivolumab
5
Immunotherapy
5
Immune Checkpoint Inhibitors
5
Chemotherapy, Adjuvant
5
Carboplatin
5
palbociclib
4
manganese chloride
4
Surgical Procedures, Operative
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Neoplasm Metastasis
×
pyrotinib
×
Clear all
NCT04355858
2022-07-26
MULAN
Fudan University
Phase 2
Unknown
319 enrolled